About Sun Pharma
Sun Pharma was a pioneer among Indian pharmaceutical companies in investing in research and development. Early investment, beginning three decades ago, made technology the company’s key differentiator and produced a broad basket of robust products for markets across the world.
Its core strength is developing generics and technologically complex products through focused teams in formulations, process chemistry and analytical development, delivering quality products within established timelines and at low cost without compromising on quality.
Around 2,000 research scientists work in multiple R&D centres equipped with cutting-edge technologies. Their expertise spans generics, technology-intensive products, active pharmaceutical ingredients, novel drug delivery systems and new chemical entities, including liposomal products, inhalers, lyophilised injections, nasal sprays and controlled-release dosage forms.
Sun Pharma’s 408-bed clinical pharmacology unit performs bioequivalence and bioavailability studies in compliance with GCP, with a full site for Phase I clinical studies. The unit has been audited by the US FDA, ANVISA, MHRA and DCGI, among others.